Physician profile
Iris Martinez
NPI 1780919589
$1,637.63
in general payments reported to CMS, 2019-2025
12 companies · $845 in 2025
The $845 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.38 · 2022: $65.59 · 2023: $239 · 2024: $443 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434 · Education: $93.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.56 |
| Education | $93.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.33 | 2023-2025 | |
| Janssen Biotech, INC. | $235.48 | 2025 | Tremfya, Simponi Aria, Stelara |
| Ardelyx, INC. | $191.92 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $170.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $152.11 | 2021-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.95 | 2021-2025 | Xifaxan |
| Pfizer INC. | $102.88 | 2022-2025 | |
| Celgene Corporation | $38.98 | 2022-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $21.38 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Abbott Laboratories | $14.88 | 2025 | Freestyle Libre 3 |
| Redhill Biopharma INC. | $14.18 | 2023 | Aemcolo, Talicia, Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.